Simvastatin Exerts Favourable Effects on Neointimal Formation in a Mouse Model of Vein Graft  by Zhang, L. et al.
Eur J Vasc Endovasc Surg (2011) 42, 393e399Simvastatin Exerts Favourable Effects on Neointimal
Formation in a Mouse Model of Vein GraftL. Zhang*, H. Lu, J. Huang, Y. Guan, H. SunDepartment of Cardiology, The Second Affiliated Hospital of Nantong University, Nantong University, Nantong 226001,
PR China
Submitted 16 September 2010; accepted 19 May 2011
Available online 20 June 2011KEYWORDS
Vein graft disease;
Simvastatin;
Vascular smooth muscle
cell* Corresponding author.
E-mail address: lizhang58@hotmai
1078-5884/$36 ª 2011 European Socie
doi:10.1016/j.ejvs.2011.05.016Abstract Background: Simvastatin inhibits human saphenous vein neointima formation in
human saphenous vein organ cultures. However, it is not known if simvastatin actually inhibits
vein graft intima hyperplasia in vivo, and the underlying mechanisms behind that. In this study,
we used a murine vein graft model to address these issues.
Methods and results: Vein grafting was performed among C57BL/6 J mice treated with low-
dose (2 mg kg1) or high-dose (20 mg kg1) simvastatin or vehicle subcutaneously 72 h before
and then daily after surgery. As compared to the vehicle, simvastatin dose-dependently signif-
icantly inhibited vein graft intima hyperplasia 4 weeks after surgeries. Immunohistochemistry
studies suggested that vein graft neointima was mainly composed of vascular smooth muscle
cells (VSMCs), and the rate of proliferating cell nuclear antigen (PCNA)-positive cells in the
intima of vein grafts was significantly lower in simvastatin-treated groups than in control
group. We isolated VSMC from mouse vena cava, simvastatin significantly reduced VSMC prolif-
eration, and platelet-derived growth factor (PDGF)-induced VSMC migration in a dose-
dependent manner.
Conclusion: Simvastatin inhibits neointima formation of mouse vein graft under normocholes-
terolaemic condition in vivo, the mechanisms might be associated with inhibitory effects of
simvastatin on VSMC proliferation and migration.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Coronary bypass grafting using autologous internal
mammary arteries and saphenous veins (SVs) is routinely
used for treatment of patients with multivessel coronary
artery disease. However, the development of intimal
hyperplasia and obstructive disease is significantly more
common in venous grafts than in arterial grafts, withl.com (L. Zhang).
ty for Vascular Surgery. Publisheapproximately 40% of vein grafts (VGs) occluding within 10
years after coronary artery bypass graft (CABG).1 Because
of a shortage of arterial graft material and the relative ease
of harvesting long vascular segments, SVs are still widely
used. In view of the large numbers of patients receiving SV
grafts (SVGs), the development of therapeutic strategies to
prevent SVG stenosis is at the forefront of clinical research.
There is good evidence showing that 3-hydroxy-3-
methylglutaryl CoA reductase inhibitors (statins) cand by Elsevier Ltd. All rights reserved.
394 L. Zhang et al.reduce SVG occlusions and improve cardiovascular outcome
after CABG,2 irrespective of whether treatment is initiated
pre-3,4 or post-operatively.5,6
Statins are a class of drugs that are used to reduce
plasma cholesterol levels in patients with hyper-
cholesterolaemia. A number of large clinical trial results
have related statin-induced cholesterol lowering to the
significant improvement in cardiovascular morbidity and
mortality.7,8 Moreover, their clinical benefits appear
greater than would be expected from simply lowering
cholesterol, and it is becoming increasingly clear that these
agents have favourable direct vascular effects independent
of cholesterol lowering.9 For example, a number of animal
studies have demonstrated that statins reduce neointima
formation following arterial injury independently of effects
on cholesterol synthesis.10e12 Statins act by inhibiting
synthesis of intracellular mevalonate which, in addition to
its central role in cholesterol synthesis, is also a precursor
of farnesyl pyrophosphate (FPP) and geranylgeranyl pyro-
phosphate (GGPP), isoprenoids required for prenylation of
Ras and Rho-family guanosine triphosphatases (GTPases),
respectively.13 This ability of statins to inhibit the pre-
nylation and resultant activity of small GTPases may
underlie many of their cholesterol-independent effects.
The molecular and cellular processes that regulate
intimal hyperplasia within VG are poorly understood and
significantly different from those that regulate intimal
hyperplasia in native arteries. Hence, mechanistic studies
are needed to define the pathogenesis of VG intimal hyper-
plasia and develop new preventive and therapeutic strate-
gies. It had been reported that simvastatin inhibits human SV
neointima formation in human SVorgan cultures.13 However,
it is not known if simvastatin actually inhibits VG intima
hyperplasia under normocholesterolaemic condition in vivo,
and the underlyingmechanisms behind that. In this study,we
used a murine VG model to address these issues.
Materials and Methods
Mice
Male C57BL/6 J (25e30 g, 12e16-week-old) mice, provided
by the Animal House, Nantong Medical College, were caged
in groups of three with normal chow and water given ad
libitum. The animals were kept in a temperature-
controlled environment (21 C) on a 12-h lightedark
cycle. All animal experiments were carried out in accor-
dance with the United States National Institutes of Health
Guide for the Care and Use of Laboratory Animals. All
surgical procedures and morphometric and immunohisto-
chemical analyses were performed with the investigators
blinded to different mouse groups.
Simvastatin treatment
Simvastatinwaspurchased fromMerck&Co., Inc. Treatments
were via subcutaneous injection 72 h before and daily after
surgery. C57BL/6 J mice were divided into three treatment
groups: phosphate-buffered saline (PBS) vehicle (control
group, nZ 8), or 2 mg kg1 (low-dose, nZ 9) or 20 mg kg1
(high-dose, nZ 9) alkaline-hydrolysed simvastatin.Vein grafting surgery
Surgery was performed as described.14 In brief, the right
common carotid artery of an anaesthetised male mouse
was ligated proximally and distally and transected at its
mid-portion. The transected ends were each passed
through polyethylene cuffs, everted back over the cuffs,
and tied to them with 8.0 silk ligatures. A segment (1 cm) of
inferior vena cava (IVC) was cut from a different (donor)
male mouse injected with 0.2 ml of saline solution con-
taining 100 units of heparin by mouse tail vein, and rinsed
with saline containing 100 U ml1 heparin, after which the
vena cava from donor mice was grafted between the two
ends of the carotid artery by ‘sleeving’ the ends of the vein
over the artery cuffs and secured with 8/0 silk sutures.
Blood flow was restored by removing the haemostats from
the carotid artery, after which the wound was closed and
sutured and the animal was allowed to recover from
anaesthesia.Morphometric analyses
Four weeks after surgery, the mouse was anaesthetised and
the VGwas surgically exposed. The vasculaturewas perfused
with PBS and 4% phosphate-buffered paraformaldehyde for 2
and 5 min, respectively. The VG was embedded in paraffin.
Three cross sections (5 mm thick, 70 mm between sections)
from its mid-portion were prepared, mounted and stained
with haematoxylin and eosin. Microscopic images were
imported into Image-Pro Plus (Media Cybernetics) and
lumen-vascular wall and tunicamediaeadventitia interfaces
were traced. Neointima area was defined as the difference
between the two traced cross-sectional areas.15 Mean neo-
intima area value of cross sections from each VG was
calculated. Intimal thickness was measured at four pre-
specified locations e that is, 3, 6, 9 and 12 o’clock e in
three cross sections of each VG and calculated mean intimal
thickness for each graft.Immunohistochemistry
Cross sections obtained from the mid-portions of VGs were
mounted on slides, de-paraffinised, hydrated, incubated
for 10 min in methanol containing 3% H2O2 and rinsed with
PBS. Antigens were detected using the Histomouse-MAX Kit
(Invitrogen). The following primary antibodies were used:
(1) mouse anti-smooth muscle a-actin monoclonal antibody
(clone 1A4, Santa Cruz Biotechnology) and (2) mouse anti-
proliferating cell nuclear antigen (PCNA) monoclonal anti-
body (Santa Cruz Biotechnology). After washing, cross
sections were incubated with secondary antibody (included
in the kit), washed, incubated with peroxidase substrate
(DAB), counterstained with haematoxylin and examined by
light microscopy. The percentage of PCNA-positive cells
was determined from analysis of >50 cells per cross
section; mean values for each group were calculated.
Negative control reactions lacking primary antibodies
confirmed the specificity of each antibody. The same anti-
body dilutions, incubation times and washing conditions
were used for all samples.
Simvastatin and Vein Graft Disease 395Isolation of venous SMC
Lines of cultured venous SMC, each isolating from the IVC of
a single mouse, were established by digesting veins with
collagenase (Worthington) after carefully removing loose
adventitia, as described.16 Venous SMCs were grown under
standard conditions in Dulbecco’s modified eagle medium
(DMEM)/F12 medium supplemented with 20% foetal bovine
serum (FBS). Immunohistochemical analyses of established
cell lines revealed homogeneous, smooth-muscle-a-actin-
positive cells. Cells were passaged a maximum of 5 times
before being used in experiments.
SMC proliferation MTT assay
For the preparation of proliferation experiments, SMCs
were seeded onto 96-well plates at a density of 1  104 per
well in the culture medium DMEM/F12, which was supple-
mented with 5% or 10% FBS and without or with simvastatin
at different concentrations (0.3, 1, 3 mM), at 37 C in a 5%
CO2 incubator for 3 days. Cell Proliferation Kit I (Roche) was
used for MTT mitochondrial function assay. Insoluble purple
formazan crystals form if the cell mitochondria are func-
tioning and the cells are viable. On the day of assay, the
culture media were replaced with serum-free medium.
SMCs were incubated with MTT labelling reagent for 4 h at
37 C in a 5% CO2 incubator. The formed purple formazan
crystals were solubilised with solubilisation solution and
mixed thoroughly with a pipette. Optical density of con-
verted dye was measured at a wavelength of 550 nm and
a reference wavelength of 650 nm with a spectrophotom-
eter (SpectraMax 340, Molecular Devices). Each determi-
nation was performed in triplicate. Results were expressed
as the relative percentage of viability as follows: relative
percentage of viability Z mean OD550/650 in test/
control  100. The concentrations of simvastatin tested
were 0.3, 1 or 3 mM. Simvastatin was dissolved in ethanol
and vehicle was added to the control group at the same
concentration. The final concentration of ethanol in both
the treated and control groups was <0.1%.
SMC migration assay
Migration assays were performed using gelatin-coated
modified Boyden chambers (Costar) with 8-mm pores in 24-
well tissue culture plates. SMCs were quiesced with serum-
free DMEM/F12 containing insulinetransferrineselenium-A
supplement (GibcoBRL) for 72 h, trypsinised lightly with
TrypLE Express (GibcoBRL) and resuspended in DMEM/F12
supplemented with 0.25% FBS (migration medium). Platelet-
derived growth factor (PDGF, R &D Systems) was prepared at
10 ng ml1 in migration medium and loaded (600 ml) into the
lower wells. SMCs were subsequently loaded into the upper
wells (2  104 cells in 100 ml). Simvastatin at appropriate
concentrations (0.3, 1 or 3 mM) was added to the upper and
lower chambers of the experimental wells and incubated for
9 h at 37 C. The control wells contained PDGF only. The cell
suspension was aspirated and unmigrated cells were scrub-
bed and rinsed twice from the top of the membranes with
cotton swabs and PBS. Diff-Quick Stain Kit (Siemens
Healthcare Diagnostics) was used to stain the membrane.The membranes were then detached from the inserts and
mounted for microscopic examination. Cell nuclei on the
underside of each membrane were counted in four random
high power fields (200) under a light microscope. SMC
migration in the experimental groups was expressed asmean
number of migrated cells per high power field.
Statistical analyses
Results are expressed as mean  standard error of the mean
(SEM). One-way analysis of variance with multiple compar-
ison procedures (HolmeSidak method) and the Student’s t-
test were used, as appropriate, to compare differences
between groups. A probability (P) value of <0.05 was
considered to indicate a statistically significant difference.
Results
Simvastatin decreases neointimal thickening
Vein grafting surgeries were performed in C57BL/6 J mice
treated with 2 or 20 mg kg1 simvastatin or vehicle
subcutaneously 72 h before and then daily after surgery
until euthanasia. In mice receiving vehicle, intimal area
after surgery progressed significantly at 28 days
(0.19  0.010 mm2). As compared to vehicle, low- and
high-dose simvastatin significantly reduced intimal area at
28 days (0.12  0.0054 and 0.077  0.0078 mm2, P < 0.05,
respectively). The neointima area of VG was significantly
less in high-dose simvastatin-treated group than in
low-dose treated group (0.12  0.0054 vs.
0.077  0.0078 mm2, P < 0.05). The results revealed that
simvastatin dose-dependently decreased intimal area in
this VG model (Fig. 1D). Simultaneously, we measured
intimal thickness at four pre-specified locations and
calculated mean intimal thickness for each graft; the
results were concordant with the intimal area data. It was
shown that intimal thickness in simvastatin groups
(40  1.8 and 31  3.4 mm) significantly reduced compared
to that in the control group (56  3.7 mm, P < 0.05,
respectively) in a dose-dependent manner (Fig. 1E).
A SMC-rich neointima developed within 4 weeks of
vein grafting
Significant intimal hyperplasia was observed in all VGs at 4
weeks after initial surgery (Fig. 1). Smooth muscle ɑ-actin
immunostaining displayed that VG neointima was composed
mainly of SMCs (Fig. 2A). Thrombus formation was not
observed within VGs at 4 weeks after surgery.
Effects of simvastatin on cell proliferation in VG
neointima
The % of actively proliferating (PCNA-positive) cells in the
VG neointima was significantly higher in control group mice
(52  2.5%) than in the simvastatin-treated group mice
(39  3.9% and 27  2.6%, P < 0.05, respectively), and the
mean percentage of PCNA-positive cells in the low-dose
simvastatin-treated group was significantly higher than in
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Figure 1 Photomicrographs of cross sections of mouse vein grafts (A through C). Haematoxylin-eosin staining 28 days after
surgery: vehicle (A); low-dose simvastatin (B); high-dose simvastatin (C). Boundaries of neointima were indicated by arrows. Scale
bars in A, B, C, represented 50 mm. Bar graphs depicting reduced neointima area (D) and thickness (E) in high-dose simvastatin-
treated mice (20 mg/kg, subcutaneously, nZ 9) and low-dose treated mice (2 mg/kg, subcutaneously, nZ 9) 28 days after surgery,
in comparison with that in vehicle treated mice (PBS, subcutaneously, nZ 8), *P < 0.05 versus control group, P < 0.05 versus low-
dose treated group, SV, simvastatin.
396 L. Zhang et al.the high-dose simvastatin-treated group (39  3.9% vs.
27  2.6%, P < 0.05), suggesting that simvastatin dose-
dependently inhibited cell proliferation within neointima
of the VG wall (Fig. 2B and C).
Effects of simvastatin on venous SMC proliferation
We analysed the effects of simvastatin on the growth of
venous SMC by MTT assay. The concentrations of simvasta-
tin tested were 0.3, 1 and 3 mM in DMEM supplemented with
5% or 10% FBS, respectively. The relative percentage of
venous SMCs viability in groups treated with simvastatin at
the above concentrations decreased to 85  5.4%,
95  3.1%; 55  1.6%, (P < 0.01), 64  2.0%, (P < 0.05); and
49  6.7%, (P < 0.05), 55  3.5%, (P < 0.05) in comparison
with those in the control group (100  0.6% and
100  5.7%). Simvastatin had a significant inhibitory effecton venous SMC growth in a dose-dependent manner under
different FBS concentrations as compared to vehicle
(Fig. 3).
Effects of simvastatin on venous SMC migration
SMC migration is an important determinant of intimal
hyperplasia. We studied the functional effect of simvasta-
tin on venous SMC migration through gelatin-coated
membranes. Cell migration was dose-dependently inhibi-
ted with simvastatin. Results represented three indepen-
dent experiments. Compared with that in the control
(245  7), the mean number of migrated venous SMCs per
high power field was significantly reduced to 213  9
(P < 0.05), 159  5 (P < 0.05) and 122  6 (P < 0.05) in the
groups treated with simvastatin at the concentrations of
0.3, 1 and 3 mM, respectively (Fig. 4).
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Figure 2 Immunohistochemical analyses of cross sections from vein grafts 4 weeks after implantation. Anti-smooth-muscle-a-
actin immunostaining (A); anti-proliferating cell nuclear antigen (PCNA) immunostaining (B); Quantification of PCNA-positive
nuclei: from left to the right, control group, n Z 8; low-dose simvastatin-treated group, n Z 9; high-dose simvastatin-treated
group, n Z 9; * P < 0.05 versus control group, P < 0.05 versus low-dose treated group (C).
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Statins are a class of drugs prescribed to individuals with
hypercholesterolaemia. Aggressive lipid controlling therapy
is quite attractive to avoid post-CABG VG disease and the
studies indicated that it may be effective to maintain the
long-term graft patency.5 In addition to their primary func-
tion of lowering plasma cholesterol levels, statins also have
beneficial effects on the cardiovascular system through
lipid-independent mechanisms. There is increasing clinical
evidence that statins can reduce the incidence of CABG0%
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Figure 3 Effect of simvastatin on the viability of venous
SMCs was measured by the MTT assay. Cells were exposed
to various concentrations of simvastatin (0.3, 1, 3 mM) for
72 h with 5% (left) or 10% (right) foetal bovine serum (FBS).
*P < 0.05 compared with control group; SV, simvastatin.occlusion in SV conduits, which is independent of cholesterol
levels.2,3,17 Recently, Antoniades and colleagues reported
that short-term treatment with atorvastatin before CABG
improves redox state in SVGs, by inhibiting vascular Rac1-
mediated activation of NADPH-oxidase.18 Indeed, statin
therapy can retard the progression of VG disease and reduce
the need for repeat revascularisation procedures,19 but the
exact mechanisms are still under investigation. The under-
lying pathology of SV graft occlusion is intimal hyperplasia,
a process initiated by endothelial damage during vein har-
vesting and implantation. The resultant increase in the
expression of inflammatory mediators such as PDGF and
interleukin-1 (IL-1) inducesmatrixmetalloproteinase (MMP)-
2 and 9 activity, which permits intimally directed SMC
migration and proliferation.20,21 It had been demonstrated
using organ-cultured human SV or SV-derived SMC cultures
that statins reduce neointima formation, MMP-9 secretion
and SV SMC invasion and proliferation.22 However, it is
unknot known if simvastatin actually inhibits VG intima
hyperplasia under normocholesterolaemic condition in vivo,
and the roles of simvastatin in mouse venous SMC prolifera-
tion and migration.
Our study provided definitive evidence that simvastatin
caused a dose-dependent reduction of neointima formation
in a murine model of VG disease. In this study, we chose low
dose (2 mg kg1) or high dose (20 mg kg1) as simvastatin
treatments following the published paper.23 But for
a translational study, a mouse dose of 2 mg kg1 is equiv-
alent to a human dose of 0.14 mg kg1 (about 10 mg day1),
and 20 mg kg1 equals 1.4 mg kg1 (about 100 mg day1);
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Figure 4 Simvastatin inhibits venous SMCs migration. Venous SMCs were seeded in the upper chamber of transwells (2  104 cells
in 100 mL medium per well). Simvastatin at appropriate concentrations was added to the upper and lower chambers of the
experimental wells and incubated for 9 h at 37 C. The control wells contained PDGF only. Data represented results from 3
independent experiments. Representative stained membranes from each treatment group at the end of the migration period (A);
bar graph depicting the effect of simvastatin treatments on venous SMC chemotaxis to PDGF (B). *P < 0.05 versus control group; SV,
simvastatin.
398 L. Zhang et al.the latter looks too high, as higher doses of simvastatin
(160 mg day1) have been found to be too toxic in clinic,
while giving only minimal benefit in terms of lipid lowering.
In secondary prevention, 80 mg day1 reduced major
cardiovascular events by an absolute rate of 1.2% compared
to 20 mg day1 in a randomised controlled trial.24 The male
C57BL/6 J mice were used, and no significant changes could
be observed in plasma lipid level after simvastatin treat-
ments (data not shown); the results supported that the
effect of simvastatin on neointima formation was in a lipid-
independent manner. Similarly, Steinmetz and colleagues
reported that treatment with simvastatin (2 mg kg1 day1,
subcutaneously) suppresses the development of experi-
mental abdominal aortic aneurysms in C57BL/6 J wild-type
mice.25 The molecular and cellular processes that regulate
intimal hyperplasia within VGs are poorly understood. In
this study, immunohistochemical analyses revealed that VG
neointima was mainly composed of SMCs, and the rate of
proliferating (PCNA-positive) cells in the intima of VGs was
significantly lower in the simvastatin-treated groups than in
the control group. Statins inhibit the synthesis of isoprenoid
intermediates that are important lipid attachments for
signalling proteins, including Ras and Rho family of small
guanosine triphosphate (GTP)-binding proteins (e.g., Rho,
Rac and Cdc42).26 Rho is implicated in various biological
functions, including cellular migration, proliferation and
survival.27,28 Statins attenuate vascular SMC proliferation
in vitro by decreasing Rho geranylgeranylation and
membrane localisation and inhibiting Cdk activity.22 It had
been reported that PDGF-induced phosphorylation of Akt is
inhibited in aortic tissue from simvastatin-treated mice.
The effects of statins on Akt signalling seem to be tissue
specific. Statins rapidly activate Akt signalling in endothe-
lial cells, enhance phosphorylation of endothelial NOsynthase and inhibit apoptosis.29 By contrast, statins impair
Akt activation in SMCs,30 leading to diminished SMC prolif-
eration and induction of apoptosis via effects on
phosphatidylinositol-3 kinase or Rho.22 These divergent
actions of statins on Akt activation in endothelial cells and
SMCs may act in synchrony to diminish neointimal thick-
ening after VG surgery. We isolated VSMC from mouse vena
cava; simvastatin significantly inhibits venous SMC prolif-
eration and PDGF-induced venous SMC migration.
In conclusion, we found for the first time that simvas-
tatin dose-dependently inhibited the neointima formation
in a mouse VG model with normal plasma cholesterol level,
and reduced mouse VSMC proliferation and migration
in vitro. These novel findings may have major clinical
implications, because they support the notion that even in
patients with relatively low low-density lipoprotein (LDL),
treatment with statins has direct beneficial effects on the
biology of SVGs used in CABG and may have an impact on
the patency of these grafts. However, the model that we
used is not an experimental system for studying lumen
stenosis, but rather early intimal hyperplasia, and this
process of early intima hyperplasia, in itself, rarely
produces significant stenosis, which represents the foun-
dation for later development of graft atheroma.
Conversely, in this mouse VG model, the inferior vena cava
was grafted into the common carotid artery by using
‘cuffs’, thus avoiding direct anastomosis. The operation
procedure of this model is relatively simple as compared to
other VG models, and the traumatic and ischaemic injuries
to the grafts are minimal. The major disadvantage of this
model is that cuff anastomoses are not used clinically. We
tried to anastomose the ends of the vein segment and
arteries using a suture, and found that the cuff technique
was easier to obtain a reproducible result. In the near
Simvastatin and Vein Graft Disease 399future, additional research may lead to further under-
standing of the actions of statins, and will support the
proposal of an earlier and more aggressive use of statins for
patients with CABG.
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